GlassScriptPhysician profile
Farooq Akbar
NPI 1396772117
$1,828.51
in general payments reported to CMS, 2019-2025
35 companies · $793 in 2025
The $793 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.15 · 2021: $133 · 2022: $40.46 · 2023: $499 · 2024: $277 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,549 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,549.48 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $186.27 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $176.17 | 2023-2025 | Darzalex, Talvey, Tecvayli |
| Novartis Pharmaceuticals Corporation | $161.88 | 2021-2025 | |
| Pfizer INC. | $150.52 | 2023-2025 | |
| Daiichi Sankyo INC. | $113.55 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Regeneron Healthcare Solutions, INC. | $95.95 | 2022-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $88.10 | 2019-2025 | Imfinzi |
| Lilly USA, LLC | $63.69 | 2023-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $51.91 | 2023-2025 | Reblozyl |
| Genentech USA, INC. | $51.51 | 2021-2025 | Tecentriq, Polivy |
| Takeda Pharmaceuticals U.S.A., INC. | $50.27 | 2024-2025 | Ninlaro, Fruzaqla |
| Tersera Therapeutics LLC | $49.24 | 2025 | Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $45.88 | 2023-2025 | |
| Incyte Corporation | $40.98 | 2023-2025 | Zynyz, Monjuvi, Jakafi |
| Taiho Oncology, INC. | $37.83 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $35.26 | 2023-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $34.67 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $34.24 | 2023 | Orgovyx |
| Glaxosmithkline, LLC. | $32.58 | 2024-2025 | Zejula, Jemperli |
| Coherus Oncology, INC. | $27.95 | 2023 | |
| Foundation Medicine, INC. | $26.99 | 2023 | Foundationone Cdx |
| Stemline Therapeutics INC. | $26.24 | 2023 | Orserdu |
| Geron Corporation | $26.17 | 2025 | Rytelo |
| Abbvie INC. | $24.94 | 2025 | |
| Pharmaand Gmbh | $24.36 | 2025 | Rubraca |
| Tolmar, INC. | $24.36 | 2025 | Eligard, Rubraca |
| Genzyme Corporation | $19.36 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $19.21 | 2025 | Onivyde |
| Beigene USA, INC. | $18.80 | 2021 | |
| Clovis Oncology, INC. | $16.37 | 2019 | |
| Exelixis INC. | $15.86 | 2021 | |
| Puma Biotechnology, INC. | $15.50 | 2021 | |
| Array Biopharma INC | $15.46 | 2023 | Mektovi, Braftovi, Lorbrena |
| Rigel Pharmaceuticals, INC. | $14.10 | 2023 | Rezlidhia, Tavalisse |
| Astellas Pharma US INC | $12.34 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Farooq Akbar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.